Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS)

医学 光谱(功能分析) 物理 量子力学
作者
Guillaume Canaud,Juan Carlos López‐Gutiérrez,Alan D. Irvine,P. Vabres,Jordan R. Hansford,Nii Ankrah,Fabrice Branle,Athanasia Papadimitriou,Antonia Ridolfi,P.R. O'Connell,Stuart Turner,Denise M. Adams
出处
期刊:Genetics in Medicine [Elsevier BV]
卷期号:25 (12): 100969-100969 被引量:47
标识
DOI:10.1016/j.gim.2023.100969
摘要

Purpose PIK3CA-related overgrowth spectrum (PROS) encompasses several rare conditions resulting from activating variants in PIK3CA. Alpelisib, a PI3Kα-selective inhibitor, targets the underlying etiology of PROS, offering a novel therapeutic approach to current management strategies. This study evaluated the safety and efficacy of alpelisib in pediatric and adult patients with PROS. Methods EPIK-P1 (NCT04285723) was a non-interventional, retrospective chart review of 57 patients with PROS (≥2 years) treated with alpelisib through compassionate use. Patients had severe/life-threatening PROS-related conditions and confirmed PIK3CA pathogenic variant. The primary end point assessed patient response to treatment at Week 24 (6 months). Results Twenty-four weeks (6 months) after treatment initiation, 12 of 32 (37.5%) patients with complete case records included in the analysis of the primary end point experienced a ≥20% reduction in target lesion(s) volume. Additional clinical benefit independent from lesion volume reduction was observed across the full study population. Adverse events (AEs) and treatment-related AEs were experienced by 82.5% (47/57) and 38.6% (22/57) of patients, respectively; the most common treatment-related AEs were hyperglycemia (12.3%) and aphthous ulcer (10.5%). No deaths occurred. Conclusion EPIK-P1 provides real-world evidence of alpelisib effectiveness and safety in patients with PROS and confirms PI3Kα as a valid therapeutic target for PROS symptom management.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
晓晓完成签到,获得积分10
1秒前
AAA发布了新的文献求助10
2秒前
null的应助被AURORA采纳,获得10
2秒前
wanci的应助被慕你你你你你采纳,获得10
2秒前
强强完成签到,获得积分10
2秒前
思源的应助被haifang采纳,获得10
3秒前
4秒前
小蘑菇的应助被梦锂铧采纳,获得10
4秒前
SciGPT的应助被Wxh采纳,获得30
4秒前
顺利怜菡发布了新的文献求助10
4秒前
summertny完成签到,获得积分10
5秒前
6秒前
6秒前
6秒前
hc发布了新的文献求助10
6秒前
6秒前
7秒前
专注科研发布了新的文献求助10
7秒前
Kenny完成签到,获得积分10
7秒前
8秒前
leajay发布了新的文献求助10
8秒前
Nowaki发布了新的文献求助10
8秒前
YEZI完成签到 ,获得积分10
8秒前
Jasper的应助被孤独的冷安采纳,获得10
8秒前
充电宝的应助被zhangkai6633采纳,获得10
9秒前
9秒前
10秒前
10秒前
10秒前
10秒前
10秒前
10秒前
10秒前
10秒前
10秒前
10秒前
CodeCraft的应助被洪茜茜采纳,获得10
10秒前
危机的白柏完成签到 ,获得积分10
11秒前
渣渣辉发布了新的文献求助10
12秒前
pillowpiger发布了新的文献求助10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163922
求助须知:如何正确求助?哪些是违规求助? 9557995
关于积分的说明 21743022
捐赠科研通 7754548
什么是DOI,文献DOI怎么找? 3428401
关于科研通互助平台的介绍 2553053
邀请新用户注册赠送积分活动 2473008